PITTSBURGH, Pennsylvania —Lipella, an early-stage biotech company focusing on bladder-based ailments, is raising $1 million, according to a filing with the Securities and Exchange Commission.
Lipella is researching therapies for urinary bladder dysfunction, including treatments for overactive bladder, superficial bladder cancer and interstitial cystitis, which is also known as painful bladder syndrome.
The treatments are delivered into the bladder: a more direct delivery approach than many therapies that the company says will cut side effects and is often easily reimbursable.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Lipella’s lead product treats bladder irritation.
The four-year-old company has received seed level investments including from the Pittsburgh Life Sciences Greenhouse.
